Preclinical profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a new duocarmycin-based linker-drug platform

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2618-2629

  Dokter, Wim ^a   Ubink, Ruud ^a   Van Der Lee, Miranda ^a   Van Der Vleuten, Monique ^a   Van Achterberg, Tanja ^a   Jacobs, Danielle ^a   Loosveld, Eline ^a   Van Den Dobbelsteen, Diels ^a   Egging, David ^a   Mattaar, Ellen ^a   Groothuis, Patrick ^a   Beusker, Patrick ^a   Coumans, Ruud ^a   Elgersma, Ronald ^a   Menge, Wiro ^a   Joosten, John ^a   Spijker, Henri ^a   Huijbregts, Tijl ^a   De Groot, Vincent ^a   Eppink, Michel ^a   De Roo, Guy ^a   Verheijden, Gijs ^a   Timmers, Marco ^a   more..

^a SYNTHON BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; DUOCARMYCIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; SYD 983; SYD 985; TRASTUZUMAB; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; DUOCARMYCIN A; ERBB2 PROTEIN, HUMAN; IMMUNOTOXIN; INDOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER GROWTH; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG PURIFICATION; DRUG SAFETY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG CANCER CELL LINE; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN TARGETING; SENSORY NEUROPATHY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; FEMALE; HUMANS; IMMUNOTOXINS; INDOLES; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; PYRROLIDINONES; RANDOM ALLOCATION; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84915751470     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0040-T     Document Type: Article

References (41)

1. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248-62.
2. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Ann rev Med 2013;64:15-29.
3. Gopal AK, Ramchandren R, O'Conner OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120:560-8.
4. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9.
5. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab-vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6.
6. Burris HAIII, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
7. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2 - positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:1-9.
8. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
9. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab vplus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013;31:1157-63.
10. Martin DG, Chidester CG, Duchamp DJ, Mizsak SA. Structure of CC-1065 (NSC 298223), a new antitumor antibiotic. J Antibiotics 1980;33:902-3.
11. Boger DL, Johnson DS. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc Natl Acad Sci USA 1995;92;3642-9.
12. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Eng J Med 2007;357:39-51.
13. Beusker PH, Coumans RGE, Elgersma RC, Menge WMPB, Joosten JAF, Spijker HJ, et al. Novel CC-1065 analogs and their conjugates. Int Patent Publ WO 2010/062171.
14. Beusker PH, Coumans RGE, Elgersma RC, Menge WMPB, Joosten JAF, Spijker HJ, et al. Novel conjugates of CC-1065 analogs and bifunctional linkers. Int Patent Publ WO 2011/133039.
15. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000;164:4178-84.
16. Smith V, Wirth GJ, Fiebig HH, Burger AM. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genom Proteom 2008;5:263-74
17. Cristofanilli M, Bryan WJ, Miller LL, Chang AYC, Gradishar WJ, Kufe DW, et al. Phase II study of adozelesin in untreated metatastic breast cancer. Anti-Cancer Drugs 1998;9:779-82.
18. Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol 2000;46:167-71.
19. Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, et al. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol 2002;25:308-12.
20. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanism of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56.
21. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82.
22. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res 2011;13:R123.
23. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005;70:1673-84.
24. Duysen EG, Koentgen F, Williams GR, Timperley CM, Schopfer LM, Cerasoli DM, et al. Production of ES1 plasma carboxylesterase knockout mice for toxicity studies. Chem Res Toxicol 2011;24:1891-8.
25. Zhang N, Liu L, Dumitru CD, Houston Cummings NG, Cukan M, Jiang Y, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 2011;3:289-98.
26. Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, et al. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 2011;26:423-30.
27. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. What have we learned? mAbs 2011;3:61-6
28. Poon KA, Flagella K, Beyer J, Tibbits J, Kaur S, Saad O, et al. Preclinical safety profile of trastuzumab-emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 2013;273:298-313.
29. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70.
30. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
31. Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 2010;37:221-42.
32. FDA report Application number 125399Orig1s000, Center for Drug Evaluation and Research, Pharmacology Review brentuximab vedotin (Adcetris), 2011.
33. Stove C, Stove V, Derycke L, van Marck V, Mareel M, Bracke M. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol 2003;121:802-12.
34. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-75.
35. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001;61:3493-3500.
36. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer and Metastasis Reviews 2003;22:271-86.
37. Podgorski I, Sloane BF. Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp 2003;70:263-76.
38. Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG, Denny WA , et al. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J Med Chem 2005;48:1344-58.
39. Jeffrey SC, Nguyen MT, Moser RF, Meyer DL, Miyamoto JB, Senter PD. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Biorg Med Chem Lett 2007;17:2278-80.
40. Thevanayagam L, Bell A, Chakraborty I, Sufi B, Gangwar S, Zang A , et al. Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications. Bioanalysis 2013;5:1073-81.
41. De Groot FMH, Beusker PH, Scheeren JW, de Vos D, van Berkom LWA, Busscher GF, et al. Elongated and multiple spacers in activatible prodrugs. Int Patent Publ WO02/083180.